Vimarsana
Biggest News Aggregation in the World

Quan Lu News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Quan Lu. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Quan Lu Today - Breaking & Trending Today

KNTV NBC Bay Area News At 5 February 1, 2018 - Vimarsana News

KNTV NBC Bay Area News At 5 February 1, 2018

Cameras although payne when i spoke with him earlier couldnt tell me what the cameras captured. We know a mom here to pick up her daughter the day is happened says she saw the whole thing. What she tells us she witnessed coming up at 6 00. Thank you. Now to the south bay. This just in. A soccer coach accused of Sexual Assault. In man is accuse ds of assaulting a minor he met while coaching. He had numerous coaching jobs including at Oak Grove High School and south bay. And south valley junior high in gilroy. Police say the Sexual Assault happened at a private home in morgan hill. Also within t...

Vesigen Therapeutics Appoints Paulash Mohsen as Chief Executive Officer - Vimarsana News

Vesigen Therapeutics Appoints Paulash Mohsen as Chief Executive Officer

Vesigen Therapeutics Appoints Paulash Mohsen as Chief Executive Officer - read this article along with other careers information, tips and advice on BioSpace

Vesigen Therapeutics Announces Issuance of U.S. Patent for Broad Applications of ARMMs Technology - Vimarsana News

Vesigen Therapeutics Announces Issuance of U.S. Patent for Broad Applications of ARMMs Technology

Share this article Share this article CAMBRIDGE, Mass., March 16, 2021 /PRNewswire/ -- Vesigen Therapeutics, Inc., a biotechnology company pioneering a novel extracellular vesicle delivery technology to develop transformative therapeutics, today announced that the United States Patent and Trademark Office has issued U.S. Patent No. 10,945,954 entitled "ARRDC1-Mediated Microvesicles (ARMMs) and Uses Thereof". This patent, exclusively licensed to Vesigen from Harvard University, broadly covers many of the drug delivery features of any ARRDC1-mediated microvesicles (ARMMs). This patent covers ...